| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 03/19/1998 | WO1998011089A1 Novel benzothiophene derivatives, their preparation and use as urokinase inhibitors |
| 03/19/1998 | WO1998011063A1 Cytostatic hydroxamic acid derivatives |
| 03/19/1998 | WO1998011049A1 Lipoxin compounds and their use in treating cell proliferative disorders |
| 03/19/1998 | WO1998010795A2 Tumor homing molecules, conjugates derived therefrom, and methods of using same |
| 03/19/1998 | WO1998010794A2 Antineoplastic conjugates of transferrin, albumin and polyethylene glycol |
| 03/19/1998 | WO1998010781A1 Means for treating prostate hypertrophy and prostate cancer |
| 03/19/1998 | WO1998010780A1 ISOLATED PEPTIDES WHICH COMPLEX WITH HLA-Cw*16 MOLECULES, AND USES THEREOF |
| 03/19/1998 | WO1998010777A1 Nucleosome-based anti-tumor compositions |
| 03/19/1998 | CA2266014A1 Tricyclic compounds useful for inhibition of farnesyl protein transferase |
| 03/19/1998 | CA2265927A1 Monoclonal antibodies against the extracellular domain of human vegf-receptor protein (kdr) |
| 03/19/1998 | CA2265925A1 Semi-allogeneic cell hybrids as preventive and therapeutic vaccines for cancer and aids |
| 03/19/1998 | CA2265861A1 Antineoplastic conjugates of transferrin, albumin and polyethylene glycol |
| 03/19/1998 | CA2265764A1 Tricyclic compounds useful as fpt inhibitors |
| 03/19/1998 | CA2265763A1 Tricyclic piperidinyl compounds useful as inhibitors of farnesyl-protein transferase |
| 03/19/1998 | CA2265670A1 Nucleosome-based anti-tumor compositions |
| 03/19/1998 | CA2265467A1 Ptx sensitive g proteins, the production and use thereof |
| 03/19/1998 | CA2265455A1 Granulocyte chemotactic protein 2 variant |
| 03/19/1998 | CA2264966A1 Expression of an exogenous gene in a mammalian cell by use of a non-mammalian dna virus having an altered coat protein |
| 03/19/1998 | CA2264666A1 Substituted benzocycloheptapyridine useful as inhibitors of farnesyl-protein transferase |
| 03/19/1998 | CA2264563A1 Isolated peptides which complex with hla-cw*16 molecules, and uses thereof |
| 03/19/1998 | CA2264541A1 Human protein kinases |
| 03/18/1998 | EP0828849A1 High-affinity oligonucleotide ligands to growth factors |
| 03/18/1998 | EP0828832A2 $g(D)P62, ITS VARIANTS, NUCLEIC ACID SEQUENCES ENCODING THEM, AND THEIR USES IN ANTI-CANCER GENE THERAPY |
| 03/18/1998 | EP0828831A2 A novel human purinergic p 2u? receptor |
| 03/18/1998 | EP0828829A1 A gene switch comprising an ecdysone receptor |
| 03/18/1998 | EP0828756A2 Diagnosis of, and vaccination against, a positive stranded rna virus using an isolated, unprocessed polypeptide |
| 03/18/1998 | EP0828743A1 Water soluble camptothecin analogs |
| 03/18/1998 | EP0828732A1 Peptidyl compounds and their therapeutic use |
| 03/18/1998 | EP0828726A1 Tricyclic inhibitors of matrix metalloproteinases |
| 03/18/1998 | EP0828724A1 Diaryl-5-oxygenated-2-(5h)-furanones as cox-2 inhibitors |
| 03/18/1998 | EP0828508A2 Compositions of interleukin and pyrimidine nucleosides |
| 03/18/1998 | EP0828507A1 Method for treatment of pain |
| 03/18/1998 | EP0828500A1 Use of flavanolignanes for the preparation of medicaments with antiproliferative activity in uterus, ovary and breast |
| 03/18/1998 | EP0828497A1 Methods of inhibiting leaderless protein export using cardiac glycosides or aglycones therefrom and derivatives |
| 03/18/1998 | EP0828490A1 RAR-beta SELECTIVE RETINOID COMPOUNDS FOR INHIBITING GENE EXPRESSION PROMOTED BY AP1 PROTEIN AND THEIR USE IN THERAPY |
| 03/18/1998 | EP0723547A4 Boronated metalloporphyrins and therapeutic methods |
| 03/18/1998 | EP0525119B1 Antibody conjugates for treatment of neoplastic disease |
| 03/18/1998 | EP0461225B1 Circumvention of human tumor drug resistance |
| 03/18/1998 | EP0460232B1 Tumor cell growth inhibitor |
| 03/18/1998 | CN1176637A Piperazine-2, 5 -dione derivatives as modulators of multidrug resistance |
| 03/18/1998 | CN1176603A Vascular endothelial growth factor-B |
| 03/18/1998 | CN1176600A Method for inhibiting ovarian cancer |
| 03/18/1998 | CN1176597A Benzothiopyranoindazoles antitumor agents |
| 03/18/1998 | CN1176252A Novel coumarin quinolone carboxylic acids and processes for preparation thereof |
| 03/18/1998 | CN1176248A Restricted 9-CIS-retinoids |
| 03/18/1998 | CN1176113A Compound bufonin of bufo gargarizans |
| 03/18/1998 | CN1037774C Phosphonooxymethyl ethers derivatives of taxane |
| 03/18/1998 | CN1037773C Heteroatoms-containing tricyclic compounds |
| 03/18/1998 | CN1037765C 脱氢方法 Dehydrogenation process |
| 03/17/1998 | US5728868 Prodrugs of protein tyrosine kinase inhibitors |
| 03/17/1998 | US5728849 Antitumor and antileukemic agents |
| 03/17/1998 | US5728846 Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives |
| 03/17/1998 | US5728845 Immunotherapeutic nitriles |
| 03/17/1998 | US5728844 Immunotherapeutic agents |
| 03/17/1998 | US5728829 Multistage reaction of n-protected benzotriazolyl glycine derivative with aminoketone, then reaction with ammonia and acid catalyzed cyclization |
| 03/17/1998 | US5728819 Secreted proteins and polynucleotides encoding them |
| 03/17/1998 | US5728805 Purified protein having antitumor activity |
| 03/17/1998 | US5728738 Mixing alkali with sodium mercaptoethylsulfonate |
| 03/17/1998 | US5728726 Method and compositions for inhibiting protein kinases |
| 03/17/1998 | US5728724 Treatment of postmenopause syndrome, osteoporosis, cardiovascular disorders and estrogen dependent cancer |
| 03/17/1998 | US5728716 Trachykinin peptide for nervous system disorders and cardiovascular disorders |
| 03/17/1998 | US5728710 Rapamycin derivatives |
| 03/17/1998 | US5728708 Pharmacologically active pyridine derivatives and processes for the preparation thereof |
| 03/17/1998 | US5728703 Administering a tricyclic compound to inhibit farnesyl protein transferase |
| 03/17/1998 | US5728687 Antitumour compositions containing taxane derivatives |
| 03/17/1998 | US5728686 Alkylxanthine phosphonates and alkylxanthine phosphine oxides and their use as pharmaceuticals |
| 03/17/1998 | US5728685 Selectin receptors for inflammation modulators |
| 03/17/1998 | US5728684 Determination of prodrugs metabolizable by the liver and therapeutic use thereof |
| 03/17/1998 | US5728541 Screening therapeutic or chemotherapeutic agents for efficacy as to a specific patient |
| 03/17/1998 | US5728537 Antigen immunogens for cancer detection in epithelial fluids |
| 03/17/1998 | US5728523 Polymerase delta mutations in colorectal tumors with replication errors |
| 03/17/1998 | US5728521 Targeted cleavage of RNA using eukaryotic ribonuclease P and external guide sequence |
| 03/17/1998 | US5728388 Contacting sample comprising tumor-sensitized cells with superantigens to produce stimulated cells, infusing into tumor bearing host |
| 03/17/1998 | US5728379 Tumor- or cell-specific herpes simplex virus replication |
| 03/17/1998 | US5728369 Radioactive phosphorus labeling of proteins for targeted radiotherapy |
| 03/17/1998 | CA1339737C Fibrin-specific and fibrinogen-specific monoclonal antibodies and their derivation from immunized germ free mice |
| 03/12/1998 | WO1998009992A2 HTm4, METHODS OF TREATMENT AND ASSAYS, AGONISTS AND ANTAGONISTS |
| 03/12/1998 | WO1998009980A1 Bh3 interacting domain death agonist |
| 03/12/1998 | WO1998009970A2 Alkylated rapamycin derivatives |
| 03/12/1998 | WO1998009961A1 Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf) |
| 03/12/1998 | WO1998009957A1 Compounds for and a method of inhibiting matrix metalloproteinases |
| 03/12/1998 | WO1998009948A2 Nitric ester derivatives and their use in urinary incontinence and other diseases |
| 03/12/1998 | WO1998009940A1 Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
| 03/12/1998 | WO1998009934A1 Matrix metalloproteinase inhibitors and their therapeutic uses |
| 03/12/1998 | WO1998009653A1 Association of no syntase inhibitors with trappers of oxygen reactive forms |
| 03/12/1998 | WO1998009647A2 Cyanidin compositions and therapeutic and diagnostic uses therefor |
| 03/12/1998 | WO1998009636A1 Semi-synthetic sulphaminoheparosansulphates having high anti-metastatic activity and reduced haemorrhagic risk |
| 03/12/1998 | WO1998009626A1 Methods for in vivo reduction of iron levels and compositions useful therefor |
| 03/12/1998 | WO1998009621A1 Fatty acid treatment |
| 03/12/1998 | WO1998009620A1 INHIBITION OF NUCLEAR TRANSCRIPTION FACTOR NF-λB BY CAFFEIC ACID PHENETHYL ESTER (CAPE), DERIVATIVES OF CAPE, CAPSAICIN (8-METHYL-N-VANILLYL-6-NONENAMIDE) AND RESINIFERATOXIN |
| 03/12/1998 | WO1998009533A1 Cocoa components, edible products having enhanced polyphenol content, methods of making same and medical uses |
| 03/12/1998 | WO1998009526A1 Antioxidant derived from lentil and its preparation and uses |
| 03/12/1998 | WO1998005792A3 A novel human leptin receptor gene-related protein |
| 03/12/1998 | WO1998004712A3 Substrate trapping protein tyrosine phosphatases |
| 03/12/1998 | WO1998001563A3 Adenovirus e4 proteins for inducing cell death |
| 03/12/1998 | WO1997049827A3 Adenoviral mediated gene transfer in adipocytes and related implants |
| 03/12/1998 | WO1997046682A3 Polynucleotides from human adult PBMC encoding secreted proteins |
| 03/12/1998 | WO1997046259A3 Chimeric toxin for targeted therapy |
| 03/12/1998 | WO1997040854A3 Polypeptide conjugates for transporting substances across cell membranes |
| 03/12/1998 | DE19638745A1 Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR) Monoclonal antibodies against the extracellular domain of the human VEGF - receptor protein (KDR) |